DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for coronary aneurysm — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCoronary aneurysm maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for coronary aneurysm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nebulette (NEBL) — NEBL is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4F14 · 1.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 2002 retrospective review of 13 Saudi children with Kawasaki disease (10 boys, 3 girls; mean age 3.4 years), 4 patients (30%) had cardiac complications, all boys. Three had coronary artery aneurysms (4–7 mm) and one had a giant aneurysm (9 mm); one of the three also had axillary and subclavian artery aneurysm. Only 2 of the 4 were treated with intravenous immunoglobulin and aspirin within 10 days of illness; one was treated on day 21, and one received aspirin alone. Aneurysmal changes persisted in 3 patients and resolved in the one patient treated early. The authors attributed the high rate of aneurysm and unusual complications to delayed diagnosis and treatment.
A 2016 case report describes a 66-year-old woman with bilateral coronary artery fistulas and a giant coronary aneurysm that ruptured, presenting as a huge mediastinal mass. The aneurysm was ligated and the mass resected; the organised haematoma was removed, and the patient was discharged without complications. The authors note that the best treatment for giant coronary aneurysm is not clear because of its rarity, but that surgical resection may be appropriate for potential serious complications.
A 2025 case report presents a 59-year-old man with angina and a 62 × 57 mm aneurysm of the proximal right coronary artery, compressing the right atrium. He was treated by implanting a drug-eluting stent from the proximal normal segment to the distal normal segment beyond the aneurysm, then two consecutive graft stents inside that stent. Post-procedurally, no contrast entered the aneurysm. The authors state that because no guidelines exist, the optimal treatment for coronary artery aneurysms remains uncertain.
A 2022 case report describes a patient who presented with acute coronary syndrome twice over six years, with progression of a giant right coronary artery aneurysm documented on the second presentation. The Heart Team decided on surgical treatment. The authors note that little is known about optimal management of giant coronary aneurysms and discuss the lack of data on antithrombotic regimens in these patients. Across all reports, sample sizes are tiny, no controlled trials exist, and no consensus on medical or interventional management has been reached. What is still missing are prospective registries, randomised comparisons of surgical, percutaneous, and medical strategies, and any validated method to stratify patients by rupture or thrombosis risk.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Saudi Medical Journal · 2002 · 12 citations
Pattern of clinical features of Kawasaki Disease
AbstractOBJECTIVE: To study the pattern of clinical features, complications, and outcome of Kawasaki disease among Saudi children. METHODS: Medical records and referral letters of all children (1997 through to 2001) diagnosed with Kawasaki disease were reviewed. This study was carried out at King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia. Collected data included clinical features, laboratory results, echocardiogram findings, therapy, complications and outcome. RESULTS: Thirteen children (10 boys, 3 girls) were reviewed, age range from 0.3 to 7 years (mean 3.4 years). Nine patients met 5 out of 6 criteria for the diagnoses of Kawasaki disease and 4 met 4 out of 6 criteria and coronary aneurysm. Thirteen patients had fever and skin rash for more than 5 days, 12 had extremity and oral mucus changes, 9 had bilateral conjunctivitis, and 7 had cervical lymph node enlargement. Other associated clinical features include diarrhea, and aseptic meningitis in 3 patients, ischemia of the fingers and toes in 2, arthritis in 2, arthralgia in one, seizure and pneumonia in one. Hepatosplenomegaly, pancytopenia and elevated liver enzymes in one, hepatomegaly and normal liver enzymes in 2 patients. Cardiac complication seen in 4 patients (30%), all of them were boys, 3 had coronary artery aneurysm (4-7 mm) and one had giant aneurysm (9mm), one of the 3 patients had axillary and subclavian artery aneurysm as well. Two out 4 patients were treated with intravenous immunoglobulin and aspirin within 10 days of illness and one was treated on day 21 and one was treated with aspirin alone. Aneurysmal changes persisted in 3 patients and resolved in one patient who was treated early. Extra-cardiac complications include reaction to intravenous immunoglobulin, coagulopathy, thrombocytopenia, hemophagocytic syndrome and ischemia of peripheral extremities. CONCLUSION: Our observation showed a high percentage (30%) of coronary aneurysm and unusual complications, this is most likely due to delay in the diagnosis and initiation of treatment.
Bilateral coronary artery fistulas with a giant coronary aneurysm complicated by aneurysm rupture
AbstractRATIONALE: Coronary artery aneurysms and fistulas are not rare conditions in clinical practice, but bilateral fistulas with a giant coronary aneurysm in just one person are quite rare. PATIENT CONCERNS: We report a case of a 66-year-old woman with these 2 coronary abnormalities accompanied with a huge mediastinum mass. INTERVENTIONS: The giant aneurysm was ligated and the mass was resected which was proved to be an organized hematoma finally. OUTCOMES: The patient was discharged soon with no complications. LESSONS: The best treatment of giant coronary aneurysm is not clear because of its rarity, surgical resection may be the right procedure for the potential serious complications like this case.
Closure of giant coronary artery aneurysm with graft stent: a case report
AbstractBACKGROUND: The presence of coronary aneurysm or ectasia has been associated with poor long-term outcomes, regardless of the presence of concomitant atherosclerotic coronary artery disease. The widespread use of new coronary imaging methods and the increase in coronary angiography applications in coronary artery disease have increased the frequency of rare coronary artery aneurysms (CAA). CASE PRESENTATION: A 59-year-old male patient applied to the cardiology outpatient clinic with angina that had been present for three to four months. The patient's electrocardiography was in normal with sinus rhythm and no signs of ischemia were observed. Transthoracic echocardiography revealed a52 × 47 mm mass, which was thought to be an aneurysm or cyst, causing compression on the right atrium. Cardiac MRI and computed tomography coronary angiography was performed and an aneurysm with dimensions of 62 × 57 mm, thought to originate from the right coronary artery (RCA), was observed. Coronary angiography of the patient showed a giant coronary aneurysm of the proximal segment of RCA. The patient was evaluated by the cardiac team.For treatment, a 3.5 × 48 mm Abbott Xience Pro DES was first implanted from the proximal normal coronary artery segment to the distal normal segment beyond the aneurysm, creating a stable platform for graft stent placement. Two consecutive 4.0 × 20 mm Papyrus-Biotronik graft stents were then implanted into this DES without leaving any gaps. Post-procedurally, no contrast passage into the aneurysm was observed. CONCLUSION: Because of the absence of available guidelines, the optimal treatment method for coronary artery aneurysms remains uncertain.
European Heart Journal - Case Reports · 2022 · 0 citations · open access
Two presentations of acute coronary syndrome with progression of giant right coronary artery aneurysm; a case report
AbstractBackground: Giant coronary aneurysms are a rare finding on coronary angiography. Given its very low prevalence, little is known about optimal management of this coronary pathology. Case summary: In this case report, we review the two presentations of a patient with acute coronary syndrome during a 6-year period. With regard to the second presentation, we review the investigations that demonstrate the progression of a coronary aneurysm in the right coronary artery as well as the Heart Team evaluations that resulted in surgical treatment of the coronary aneurysm. Discussion: Following perspectives on prevalence and risk factors, we emphasize upon the available data with regard to interventional options in coronary aneurysms and describe the considerations with regard to interventional treatment in patients with giant coronary aneurysms. Finally, we discuss the available literature with regard to antithrombotic regimens in patients with coronary aneurysms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
